While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...

BioNTech (NASDAQ:BNTX) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology ...

Investors with a lot of money to spend have taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

BioNTech (NASDAQ:BNTX – Get Free Report) was upgraded by investment analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Tuesday ...

This month, Tempus announced a multi-year collaboration with BioNTech SE. Under the collaboration, Tempus is expected to provide analytical support and computational biology expertise to BioNTech ...

Pfizer Inc. PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near ...

10.3% of Ocugen shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 4.3% of Ocugen shares are held by company insiders.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were rockstars on the ... Of course, there is also Pfizer's decision to team up with BioNTech to develop a COVID-19 vaccine. This all happened as ...

In trading on Monday, shares of BioNTech SE (Symbol: BNTX) crossed above their 200 day moving average of $92.56, changing hands as high as $94.86 per share. BioNTech SE shares are currently ...